TG Therapeutics CFO granted 90K restricted shares

TG Therapeutics CFO Sean A. Power reported an equity grant.

Rhea-AI Filing Summary

TG Therapeutics CFO Sean A. Power reported an equity grant. On 01/08/2026 he was awarded 90,000 shares of TG Therapeutics common stock at a price of $0 per share, reported as an acquisition of non-derivative securities.

These are restricted shares, with one quarter scheduled to vest on each of 01/01/2027, 01/01/2028, 01/01/2029, and 01/01/2030. After this grant, he beneficially owns 798,111 shares of common stock, including restricted shares that vest over various time periods, all held directly.

Insider Trade Summary

Grant/Award: 90,000 shares

Grant/Award 1 txn

Insider Power Sean A

Role CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	90,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 798,111 shares (Direct)

Footnotes (2)

1. F1. Reflects a grant of restricted shares, of which 1/4 will vest equally on 1/1/27, 1/1/28, 1/1/29, and 1/1/30.
2. F2. Includes shares of restricted Common Stock, which vest over various time periods.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TG Therapeutics (TGTX) report for its CFO?

TG Therapeutics reported that CFO Sean A. Power acquired 90,000 shares of common stock on 01/08/2026 through a grant of restricted shares at a price of $0 per share.

Is the TG Therapeutics CFO transaction a purchase or a grant?

The transaction is coded "A" for acquisition and is described as a grant of restricted shares, rather than an open-market purchase.

What is the vesting schedule for the 90,000 restricted TG Therapeutics shares?

The 90,000 restricted shares will vest in four equal installments, with 1/4 vesting on 01/01/2027, 01/01/2028, 01/01/2029, and 01/01/2030.

How many TG Therapeutics shares does the CFO own after this Form 4 transaction?

After the reported grant, CFO Sean A. Power beneficially owns 798,111 shares of TG Therapeutics common stock, including restricted shares that vest over various time periods.

Are the TG Therapeutics shares held directly or indirectly by the CFO?

The Form 4 indicates that the 798,111 shares are held with direct (D) ownership by the reporting person.

Does this Form 4 for TG Therapeutics involve any derivative securities?

No derivative securities are reported in the provided tables; the transaction relates to non-derivative common stock in the form of restricted shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 05:15 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Power Sean A

(Last) (First) (Middle)

3020 CARRINGTON MILL BLVD

SUITE 475

(Street)

MORRISVILLE NC 27560

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TG THERAPEUTICS, INC. [ TGTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		A		90,000(1)	A	$0	798,111(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted shares, of which 1/4 will vest equally on 1/1/27, 1/1/28, 1/1/29, and 1/1/30.

2. Includes shares of restricted Common Stock, which vest over various time periods.

	/s/ Sean A. Power	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.